A compound effective to chemotherapy-resistant cancer cells identified

October 18, 2019

A compound effective in killing chemotherapy-resistant glioblastoma-initiating cells (GICs) has been identified, raising hopes of producing drugs capable of eradicating refractory tumors with low toxicity.

Despite longstanding and earnest endeavors to develop new remedies, the prognosis of most glioblastoma patients undergoing chemotherapies and radiotherapies remains poor. Glioblastoma, a malignant glioma, has a median survival period of approximately 15 months. One of the reasons for this is the lack of methods to eradicate its cancer stem cells, or glioblastoma-initiating cells (GICs), that demonstrate tumorigenicity (ability to form tumors) and resistance to chemotherapies and radiotherapies.

In a study published in Neuro-Oncology, the collaborative research group between Hokkaido University, FUJIFILM Corporation, and the National Institute of Advanced Industrial Science and Technology (AIST) successfully cultured human GICs resistant to temozolomide (TMZ), a standard drug used for treating glioblastoma. Next, using Fujifilm's compound library, they conducted a high-throughput drug screening to identify a compound that can specifically kill or inflict damage to GICs, not normal cells such as neural stem cells and astrocytes. The efficacy of the candidate compounds was examined using cytotoxic activities, expressions of various cell markers, and tumor-suppressive activities as indicators.

Compound 10580 was successfully identified as being capable of killing or inflicting damages to GICs. The research group identified that the compound inhibited the activity of dihydroorotate dehydrogenase (DHODH), an essential enzyme for pyrimidine synthesis found in the mitochondria's inner membrane.

While analyzing the compound's efficacy, it was also discovered that the compound decreased the expression of stem cell factors in GICs, unraveling a part of its molecular mechanism. Moreover, the compound was orally administered to tumor-bearing mice, which confirmed its strong anti-cancer efficacy. The mice exhibited no visible toxicity, suggesting that the compound is non-toxic to normal cells.

"Compound 10580 is a promising candidate for developing drugs against glioblastoma and other recurring cancers. Further technological developments of a drug delivery system or 10580 derivatives, which can cross the blood-brain barrier, are needed," says Toru Kondo of Hokkaido University's Institute for Genetic Medicine who led the study.
-end-


Hokkaido University

Related Glioblastoma Articles from Brightsurf:

A therapeutic option for glioblastoma using pH-sensitive nanomicelles
A polymeric nanomicelle that effectively delivers to glioblastoma (GBM) was developed.

Experimental glioblastoma therapy shows curative powers in mice models
Houston Methodist researchers used a second-generation prodrug called MP-Pt(IV) to target the deadly cells of glioblastoma tumors and found mice harboring human glioblastoma tumors in their brains had greatly enhanced survival and weight gain when given the newly developed prodrug.

Molecules responsible for radio-resistant glioblastoma identified
Scientists have identified key molecules that mediate radioresistance in glioblastoma multiforme; these molecules are a potential target for the treatment of this brain cancer.

Study suggests new approach to improve radiation therapy resistance in glioblastoma
Laboratory research paves the way for a clinical trial to see if an FDA-approved drug used to prevent organ transplant rejection can work against glioblastoma, an aggressive type of brain tumor.

Scientists ID gene responsible for deadly glioblastoma
The discovery of the oncogene responsible for glioblastoma could be the brain cancer's Achilles' heel, one researcher says.

Deconstructing glioblastoma complexity reveals its pattern of development
Brain cancers have long been thought of as being resistant to treatments because of the presence of multiple types of cancer cells within each tumor.

Surveillance after surgery does not improve outcomes for patients with glioblastoma
A retrospective study from the University of Missouri School of Medicine and MU Health Care showed patients who underwent surveillance imaging after surgery for brain tumor resection did not have better outcomes than patients who did not have imaging and returned when they felt symptoms of recurrence.

Targeting stromal cells may help overcome treatment resistance in glioblastoma
The deadly brain cancer glioblastoma (GBM) is often resistant to chemotherapy and radiation, but new research shows targeting stromal cells -- the cells that serve as the connective tissue of the organs -- may be an effective way of overcoming that resistance.

Researchers identify immune-suppressing target in glioblastoma
Researchers at The University of Texas MD Anderson Cancer Center have identified a tenacious subset of immune macrophages that thwart treatment of glioblastoma with anti-PD-1 checkpoint blockade, elevating a new potential target for treating the almost uniformly lethal brain tumor.

Ultrasound blasts potent glioblastoma drug into brain tumor
A potent drug for glioblastoma can't be used in patients.

Read More: Glioblastoma News and Glioblastoma Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.